Astrazeneca Uk

Quetiapine Prolonged Release Becomes the Only Atypical Antipsychotic Approved for Major Depressive Disorder (MDD) as Adjunctive Therapy, and as Monotherapy for Acute Depressive Episodes Associated With Bipolar disorder.

Older News

LONDON, September 28, 2010 - AstraZeneca UK is delighted to announce that it has today received UK approval for Seroquel XL(R)[Black Triangle Drug] (quetiapine prolonged release) as an add-on treatment of major depressive episodes in patients with Major Depressive Disorder (MDD) who have had sub-optimal response to antidepressant monotherapy.

MORE..

Corporate
|
Products
|
About Me
|
Contact
|
Privacy Policy